

CORRECTION

Correction: *CPNE1* as prognostic marker and regulator of cell growth and glycolysis in endometrial cancerXin Hu¹, Pingliang Jin², Wenqun Luo¹, Gang Yu^{1,*}¹Department of Gynaecology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, 330036 Nanchang, Jiangxi, China²Department of Plastic and Aesthetic, Jiangxi Provincial Children's Hospital, The Affiliated Children's Hospital of Nanchang Medical College, 330036 Nanchang, Jiangxi, China***Correspondence**

yu_dr15@163.com (Gang Yu)

In the original publication [1], references [4], [6], [17], and [19] have been replaced (or corrected) to improve precision and relevance. The correct references are as follows:

[4] Dexter J, Lips E, DiSilvestro P. Adjuvant therapy in node-positive endometrial cancer: a focus on chemotherapy. *Current Oncology Reports*. 2022; 24: 1677–1683.

[6] Cao J, Cao R, Liu Y, Dai T. *CPNE1* mediates glycolysis and metastasis of breast cancer through activation of PI3K/AKT/HIF-1 α signaling. *Pathology, Research and Practice*. 2023; 248: 154634.

[17] Hassan D, Menges CW, Testa JR, Bellacosa A. AKT kinases as therapeutic targets. *Journal of Experimental & Clinical Cancer Research*. 2024; 43: 313.

[19] Fontana F, Giannitti G, Marchesi S, Limonta P. The PI3K/Akt pathway and glucose metabolism: a dangerous liaison in cancer. *International Journal of Biological Sciences*. 2024; 20: 3113–3125.

The authors state that these adjustments do not alter the study design, data, results, interpretation, or the overall scientific conclusions of the work.

References

- [1] Hu X, Jin PL, Luo WQ, Yu G. *CPNE1* as prognostic marker and regulator of cell growth and glycolysis in endometrial cancer. *European Journal of Gynaecological Oncology*. 2024; 45: 141–149.